An Open Label, Phase I, Rising Multiple Dose, Single Centre Study to Determine the PK and Tolerability of ZD6474 at Different Dose Levels in Chinese Patients With Solid Malignancy Tumor
Phase of Trial: Phase I
Latest Information Update: 14 Sep 2016
At a glance
- Drugs Vandetanib (Primary)
- Indications Solid tumours
- Focus Pharmacokinetics
- Sponsors AstraZeneca
- 16 Mar 2009 Planned patient number (36) added as reported by ClinicalTrials.gov.
- 16 Mar 2009 Actual end date (Nov 2007) added as reported by ClinicalTrials.gov.
- 16 Mar 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.